Madrigal PharmaceuticalsMDGL
MDGL
About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Employees: 528
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
128% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 32
111% more call options, than puts
Call options by funds: $346M | Put options by funds: $164M
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
18% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 91
13% more funds holding
Funds holding: 281 [Q4 2024] → 317 (+36) [Q1 2025]
10% more capital invested
Capital invested by funds: $7.08B [Q4 2024] → $7.81B (+$731M) [Q1 2025]
1.72% more ownership
Funds ownership: 105.23% [Q4 2024] → 106.95% (+1.72%) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$420
33%
upside
Avg. target
$445
41%
upside
High target
$460
46%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
UBS Eliana Merle | 45%upside $458 | Buy Maintained | 2 May 2025 |
B. Riley Securities Mayank Mamtani | 46%upside $460 | Buy Reiterated | 2 May 2025 |
Canaccord Genuity Edward Nash | 33%upside $420 | Buy Maintained | 2 May 2025 |
JMP Securities Jonathan Wolleben | 40%upside $443 | Market Outperform Reiterated | 24 Apr 2025 |
Financial journalist opinion
Based on 3 articles about MDGL published over the past 30 days
Positive
Market Watch
3 weeks ago
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease noncirrhotic MASH who have moderate to advanced fibrosis.
Neutral
GlobeNewsWire
3 weeks ago
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom (Rezdiffra) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission decision is anticipated in August.
Neutral
GlobeNewsWire
3 weeks ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal's 2023 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Positive
Seeking Alpha
1 month ago
In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include potential approval of Rezdiffra in Europe, Q2 '25 earnings and business development, with MDGL indicating they are keen to add to their pipeline. Results from the MAESTRO-NASH OUTCOMES trial are not expected until 2027, but recent data from MAESTRO-NAFLD-1 provide some hint of the potential efficacy of Rezdiffra in some patients with cirrhosis.
Positive
The Motley Fool
1 month ago
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.
Neutral
GlobeNewsWire
2 months ago
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH).
Positive
Seeking Alpha
2 months ago
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company is expecting a huge surge in revenues in FY2025. Most analyst firms are positive around the company's prospects, and Madrigal has some potential additional catalysts on the horizon.
Neutral
Seeking Alpha
2 months ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Positive
Zacks Investment Research
2 months ago
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Charts implemented using Lightweight Charts™